SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshires latest quarterly results are driving discussion, with weaker operating performance in insurance, particularly GEICO, contrasted with a sharp increase in share repurchases. Traders are split between viewing the buybacks and large cash reserve as signs of management confidence and questioning whether the earnings softness and limited capital deployment will weigh on the shares.

Select Sector SPDR Trust (The) - State Street Financial Select Sector SPDR ETF

Financial Select Sector SPDR Fund

XLF is drawing attention after a sharp financial-sector pullback and put-heavy options activity, prompting debate over whether traders are hedging or positioning for further weakness. Bearish concerns include credit exposure and rate pressures, while others view the decline as profit-taking within a still-resilient sector trend.

Accenture is a global professional services company that helps the world’s businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services, creating tangible value at speed and scale. The firm combines technology and leadership in cloud, data and AI with industry experience, functional expertise and global delivery capability. Its services include Strategy & Consulting, Technology, Operations, Industry X, and Song. It operates through the following geographical segments: North America, EMEA, and Growth Markets. The company was founded in 1989 and is headquartered in Dublin, Ireland.

Accenture plc - Ordinary Shares - Class A

Traders are debating whether Accenture can turn AI consulting projects into funded client deployments, with concerns that budget scrutiny and automation could squeeze billable hours and margins. Bearish commentary also points to resistance near $260 and an elevated RSI, while some investors remain positive on the companys recent run and insider buying.

NextEra Energy, Inc. engages in the provision of renewable energy. It operates through the Florida Power and Light Company (FPL) and NextEra Energy Resources and NEET (NEER). The FPL segment involves the generation, transmission, distribution, and sale of electric energy in Florida. The NEER segment produces electricity from clean and renewable sources, including wind and solar. The company was founded on December 28, 1925 and is headquartered in Juno Beach, FL.

NextEra Energy Inc

NextEras planned Dominion acquisition and its push to expand power capacity for AI data centers are fueling debate. Bulls see greater scale and exposure to rising electricity demand, while skeptics point to financing and dilution risks, regulatory hurdles, and uncertainty over whether projected data-center loads will materialize.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines initial RASONQUE launch and quarterly results are driving attention, with traders highlighting stronger-than-expected early demand while debating whether high spending and the durability of the sales ramp justify the valuation. The discussion also points to a pending European decision and first-line pancreatic-cancer trials as potential next milestones.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

Attention centers on lorundrostats upcoming FDA decision and additional clinical data, with traders debating the drugs prospects amid a steep share-price slide. Bulls point to prior positive trial results and the regulatory catalyst, while skeptics question commercialization against AstraZenecas competing Baxfendy and cite its slow launch and limited coverage.

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,366,684,616.305855 in circulation. The last known price of Stellar is 0.15346137 USD and is down -1.11 over the last 24 hours. It is currently trading on 848 active market(s) with $109,670,947.94 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

XLM is drawing attention for its persistent selloff and perceived underperformance, with traders debating whether broader crypto weakness and continued selling will push it lower or create a buying opportunity. Bulls point to Stellars institutional tokenization and payments developments, including DTCC-related plans, while skeptics argue that adoption has yet to translate into stronger token performance.

Select Sector SPDR Trust (The) - State Street Technology Select Sector SPDR ETF

Technology Select Sector SPDR Fund

XLK is drawing attention amid a technology-sector correction and concerns that concentrated AI and data-center spending may not generate adequate returns. Traders point to mostly put-heavy options activity, debating whether it reflects hedging or bearish bets, while some see the pullback as an opportunity to buy.

NRG Energy, Inc. engages in the production, sale, and distribution of energy and energy services. It operates through the following segments: Texas, East, West/Services/Other, Vivint Smart Home, and Corporate Activities. The Texas segment includes all activities related to customer, plant and market operations in Texas, other than Cottonwood. The East segment engages in all activities related to customer, plant and market operations in the East. The West/Services/Other segment is focused on all activities related to customer, plant and market operations in the West and Canada, and activities related to the Cottonwood facility and other investments. The Vivint Smart Home segment is a smart home platform that provides customers with technology, products and services to create a smarter, greener, safer home. The company was founded in 1989 and is headquartered in Houston, TX.

NRG Energy Inc.

NRGs sharp rebound after a steep, volatile decline is drawing attention, with traders debating whether dip-buying signals a recovery or merely a temporary bounce. The discussion also weighs the AI and data-center power-demand thesis against concerns about softer electricity demand, earnings pressure, and whether expected growth is already priced in.

Algorand (ALGO) is a cryptocurrency launched in 2019. Algorand has a current supply of 10,000,000,000 with 9,078,194,480.417637 in circulation. The last known price of Algorand is 0.09693394 USD and is up 3.39 over the last 24 hours. It is currently trading on 586 active market(s) with $57,858,585.39 traded over the last 24 hours. More information can be found at http://algorand.foundation.

Algorand

ALGO is drawing attention amid weak, volatile price action around the 910-cent area, with traders debating whether it can hold support and break resistance or continue lower. Bulls point to a possible altcoin rebound and Algorands quantum-resistant and tokenization features, while bears cite its prolonged underperformance and see further downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Former FDA official George Tidmarshs defamation countersuit against Aurinia and Kevin Tang has put litigation back in focus, while traders also debate extensions in the separate Lupkynis generic-patent case and hope for a settlement. Reactions include concern about added legal uncertainty and choppy trading, but no resolution of either case is established.

Aurinia Pharmaceuticals Inc. Q3 Sales Increase

(RTTNews) - Aurinia Pharmaceuticals Inc. (AUP.V) revealed earnings for third quarter of $31.70 million...

Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of +15.00% and -4.02%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2026 and provided an update on recent business progress. Financial Results Total Revenue: For the three and nine months ended September 30, 2026, total revenue was $83.7...

Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to Decline

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline

Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Aurinia Pharmaceuticals Chief Legal Officer Trades $355K In Company Stock

Revealing a significant insider sell on August 26, Stephen P Robertson, Chief Legal Officer at Aurinia Pharmaceuticals (NASDAQ:AUPH), as per the latest SEC filing.
What Happened: A Form 4 filing with the U.S. Securitiesread more...

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Aurinia Pharmaceuticals shares rise after settling patent litigation with Teva, which can launch generic voclosporin no earlier than December 2036.read more...

• Reported GAAP EPS of $0.23
• Reported revenue of $83.7M up 13.92% YoY
• Aurinia expects SG&A expense to remain substantially consistent and expects R&D expense to increase as development activities progress; quantified revenue, margin, or earnings guidance was not provided.

Aurinias R&D expense increased as development programs advanced, income tax expense rose after deferred tax assets were used, and patent infringement actions against multiple generic applicants remain ongoing.

Aurinia reported LUPKYNIS sales growth with further market penetration, initiated clinical development of aritinercept in four indications and PRESERVE, and held $486.9M in cash and investments.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH Stock Rallies 6% After-Hours  — Here’s Why 

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Under the deal, Teva agreed that two of Aurinia’s key U.S. patents, expiring in December 2037, are valid, enforceable, and would be infringed by its generic product.</li><li>Teva may not launch its version in the United States before December 7, 2036.</li><li>LUPKYNIS is Aurinia’s main commercial product, approved for treating adults with active lupus nephritis.</li></ul>Shares of Aurinia Pharmaceuticals Inc (AUPH) jumped as much as 6% after-hours on Wednesday after the company announced a patent settlement that delays a potential generic version of its key drug until late 2036.The stock gained 6% during regular trading and was trading 3% higher after-hours at the time of writing.<h2 class="st-heading-2">Settlement Details</h2>Aurinia said it and its U.S. subsidiary reached an agreement with Teva Pharmaceuticals (TEVA) resolving patent infringement litigation tied to Teva’s application to sell a generic version of LUPKYNIS. &nbsp;Under the deal, Teva agreed that two of Aurinia’s key U.S. patents, expiring in December 2037, are valid, enforceable, and would be infringed by its generic product. Teva may not launch its version in the United States before December 7, 2036, unless certain limited contingencies occur earlier, Aurinia said. Any launch also requires FDA approval. &nbsp;By locking in exclusivity against a major challenger until December 2036, Aurinia extends the period during which it can sell LUPKYNIS without direct competition from Teva.<h2 class="st-heading-2">Why The Litigation Matters</h2>LUPKYNIS is Aurinia’s main commercial product, approved for treating adults with active lupus nephritis, a serious kidney complication of lupus. Multiple companies filed applications in 2025 seeking to sell cheaper copies before the patents expire. &nbsp;Litigation against other generic makers—including Dr. Reddy’s, Hikma, Sandoz, Zydus, and others—continues in federal court in New Jersey.<h2 class="st-heading-2">Other Near-Term Catalysts And Recent Progress</h2>Aurinia continues to post solid commercial growth while expanding its pipeline. In its second-quarter results reported earlier this month, the company delivered total revenue of $83.2 million, up 19% year-over-year, and LUPKYNIS net product sales of $79.4 million.Net income rose 74% to $37.4 million, and cash and investments stood at $443.1 million after share repurchases. Management reiterated full-year 2026 guidance of $315–$325 million in total revenue and $305–$315 million in LUPKYNIS sales.On the clinical side, Aurinia recently started the PRESERVE study to test LUPKYNIS in combination with other approved lupus drugs to determine whether a multi-drug approach can improve kidney outcomes. The company has also moved its next pipeline candidate, aritinercept, into clinical development across four autoimmune diseases, creating potential longer-term growth opportunities beyond LUPKYNIS.<h2 class="st-heading-2">How Did AUPH Retail Traders React?</h2>On Stocktwits, retail sentiment around AUPH stock jumped from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.Stocktwits users cheered the settlement and now expect other litigations to also yield positive outcomes for Aurinia.<stembedurl>https://stocktwits.com/US_Bull/message/662343987</stembedurl><stembedurl>https://stocktwits.com/paperjam/message/662341041</stembedurl>Another user noted that Aurinia is now looking “increasingly attractive as a buyout target.” The user further expects the company to be acquired at a price of up to $30 per share.<stembedurl>https://stocktwits.com/Marcx123/message/662347616</stembedurl><a href="https://stocktwits.com/symbol/AUPH">AUPH stock</a> has gained 1% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/iova-stock-hits-new-52-week-high-as-shares-jump-14-what-drove-the-rally/cZYduAxRJlr">IOVA Stock Hits New 52-Week High As Shares Jump 14% — What Drove The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aurinia Pharmaceuticals logo is seen displayed on a smartphone screen

Under the deal, Teva agreed that two of Aurinia’s key U.S. patents, expiring in December 2037, are valid, enforceable, and would be infringed by its generic product.Teva may not launch its version in the United States before December 7, 2036.LUPKYNIS is A

AUPH Stock Rallies 6% After-Hours  — Here’s Why

Aurinia said it and its U.S. subsidiary reached an agreement with Teva Pharmaceuticals resolving patent infringement litigation tied to Teva’s application to sell a generic version of LUPKYNIS.  


iShares Russell 2000 ETF

Teva- Pharmaceutical Industries Ltd. - ADR

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

AUPH News